August 21, 2018

Sunil Bhonsle
Chief Executive Officer
Titan Pharmaceuticals, Inc.
400 Oyster Point Blvd., Suite 505
South San Francisco, CA 94080

       Re: Titan Pharmaceuticals, Inc.
           Registration Statement on Form S-1
           Filed August 14, 2018
           File No. 333-226841

Dear Mr. Bhonsle:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments. In some of our comments, we may ask you to provide
us with
information so we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form S-1

General

1.     We note that you have a pending request for confidential treatment.
Please be advised that
       we will not be in a position to declare your registration statement
effective until we
       resolve any issues concerning the confidential treatment request.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
 Sunil Bhonsle
Titan Pharmaceuticals, Inc.
August 21, 2018
Page 2

time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Ada D. Sarmento at 202-551-3798 or Mary Beth Breslin at
202-551-3625
with any questions.



                                                             Sincerely,
FirstName LastNameSunil Bhonsle
                                                             Division of
Corporation Finance
Comapany NameTitan Pharmaceuticals, Inc.
                                                             Office of
Healthcare & Insurance
August 21, 2018 Page 2
cc:       Fran Stoller, Esq.
FirstName LastName